Trial Profile
An Open-Label Study to Evaluate the Efficacy and Safety of a Single-Dose of Oral CEM-101 in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2019
Price :
$35
*
At a glance
- Drugs Solithromycin (Primary)
- Indications Gonorrhoea
- Focus Therapeutic Use
- Sponsors Cempra Pharmaceuticals
- 30 Jul 2013 Results were presented in April 2013 at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) according to a Cempra media release.
- 26 Apr 2013 Results will be presented at the 2013 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) according to a Cempra media release. Results were also summarised in the media release.
- 22 Oct 2012 Planned number of patients changed from 30 to 55.